Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 6/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419075 | 0.81 | TRPA1 (0.33) | ARTRPA1KMT2ANR1H2NR1H3 | |
| SCHEMBL15481059 | 0.81 | PSMD14 (0.33) | ARHSD11B1TRPA1KMT2ANR1H2 | |
| SCHEMBL17517152 | 0.81 | RXRA (0.34) | RXRAGRIN1GRIN2BARHSD11B1 | |
| SCHEMBL24910218 | 0.81 | RXRA (0.37) | RXRAGRIN1GRIN2BARHSD11B1 | |
| SCHEMBL16689550 | 0.81 | KMT2A (0.44) | KMT2AMEN1 | |
| SCHEMBL12966708 | 0.79 | RXRA (0.34) | RXRAGRIN1GRIN2BARHSD11B1 | |
| SCHEMBL20285932 | 0.79 | PIK3CD (0.45) | RXRAGRIN1GRIN2BARHSD11B1 | |
| SCHEMBL12303889 | 0.79 | TRPA1 (0.32) | ARTRPA1KMT2ANR1H2NR1H3 | |
| SCHEMBL29435597 | 0.79 | MAP3K12 (0.45) | — | |
| SCHEMBL12299837 | 0.79 | L3MBTL1 (0.41) | HSD11B1TRPA1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | AHR, MUSK, TYR | RXRA 705/4885GRIN1 4874/4885GRIN2B 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.